AbbVie Qulipta Shows Benefit In Severely Afflicted Chronic Migraine Patients
The drug could see a competitive edge over other anti-CGRP agents with new chronic migraine data plus convenience as an oral drug and potential for combination with Botox.
You may also be interested in...
Physician response to FDA’s label change limiting Rinvoq to second-line-plus has been as expected, AbbVie said. Humira passed the $20bn sales threshold in 2021, but US biosimilar competition is one year away.
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.